Spyryx Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.spyryxbio.com
Clinical Trials
5
Active:3
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Placebo Inhalation Solution
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Spyryx Biosciences, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT03229252
- Locations
- 🇨🇦
University of Calgary Heritage Medical Research Center, Calgary, Alberta, Canada
🇨🇦Ottawa Hospital Research Institute/Institut de Recherche de l'Hospital d'Ottawa, Ottawa, Ontario, Canada
🇨🇦Saint Michael's Hospital, Toronto, Ontario, Canada
A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Spyryx Biosciences, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03056989
- Locations
- 🇨🇦
Saint Michael's Hospital, Toronto, Ontario, Canada
News
No news found